Wikipedia -WSS

Wikipedia

author：explore 2025-08-25 16:35:22 - browse：172

The Senate has set its eyes on regulating insurance plans for some of the most vulnerable patients in the U.S. — the 12.5 million people eligible for both Medicare and Medicaid.

“They’re a complex group of people with a lot of chronic conditions — mental illness, frailty, disability,” said Jose Figueroa, an internal medicine physician and health policy expert at Brigham and Women’s Hospital. Over a third of these dual-eligible beneficiaries have less than a high school education, and about 90% make less than $20,000 per year.

Just around 15% of beneficiaries are eligible for both Medicare and Medicaid, but they account for a third of these programs’ spending — around $440 billion — and still don’t receive better health care, Sen. Bill Cassidy (R-La.) pointed out in a JAMA viewpoint published earlier this month. “The root cause of worse outcomes despite spending more money is a lack of coordination of care,” Cassidy wrote.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

hotspot

WSS

Why health records don't always know when patients are dead

R1 RCM gets $5.8 billion buyout offer from private equity firm

NIH study of ME/CFS points to clear biological hallmarks

Bristol Myers buys into radiopharmaceuticals with RayzeBio

PBM reform efforts get punted in Congress

Grail spinoff by Illumina should end disastrous merger attempt

entertainment

Wikipedia

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

David Ricks of Eli Lilly: best biopharma CEO of 2023

Medical leaders decry Supreme Court decision on affirmative action

Carvykti CAR

Moonlake's readout produced a cash windfall. Risks remain

Grail spinoff by Illumina should end disastrous merger attempt

Drug repurposing or repositioning? The language matters

Three trends to watch in biotech in 2024

Medical leaders decry Supreme Court decision on affirmative action

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

hotspot

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

How to keep neuroscience’s past racism from being its future

Dario to buy mental health app maker Twill in cash and stock deal

6 phony surgeries that take placebo to the extreme

Medicare Advantage beneficiaries sue Humana over algorithm use

Why palliative psychiatry is worth discussing

knowledge

hotspot

hotspot

hotspot